Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1981 1
1982 5
1983 6
1984 3
1985 5
1986 4
1987 4
1988 4
1989 3
1990 3
1991 3
1992 5
1993 5
1994 2
1996 2
1997 1
1998 4
1999 2
2000 5
2001 5
2002 5
2003 5
2004 7
2005 5
2006 4
2007 4
2008 4
2009 2
2010 8
2011 2
2012 3
2013 5
2014 5
2015 1
2017 6
2018 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

137 results
Results by year
Filters applied: . Clear all
Page 1
Follicular lymphoma international prognostic index.
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Solal-Céligny P, et al. Blood. 2004 Sep 1;104(5):1258-65. doi: 10.1182/blood-2003-12-4434. Epub 2004 May 4. Blood. 2004. PMID: 15126323 Free article.
Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.
Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, Bennouna J, Urban T, El Khouri C, Charron A, Septans AL, Balavoine M, Landry S, Solal-Céligny P, Letellier C. Denis F, et al. Among authors: solal celigny p. J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx029. J Natl Cancer Inst. 2017. PMID: 28423407 Clinical Trial.
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, Genevray M, Zharkov A, Dixon M, Brewster M, Barrett M, MacDonald D. Davies A, et al. Among authors: solal celigny p. Lancet Haematol. 2017 Jun;4(6):e272-e282. doi: 10.1016/S2352-3026(17)30078-9. Epub 2017 May 2. Lancet Haematol. 2017. PMID: 28476440 Clinical Trial.
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Feugier P, et al. Among authors: solal celigny p. J Clin Oncol. 2005 Jun 20;23(18):4117-26. doi: 10.1200/JCO.2005.09.131. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867204 Clinical Trial.
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Scagliotti GV, et al. Among authors: solal celigny p. J Thorac Oncol. 2012 Dec;7(12):1823-1829. doi: 10.1097/JTO.0b013e31826aec2b. J Thorac Oncol. 2012. PMID: 23154554 Free article. Clinical Trial.
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Federico M, et al. Among authors: solal celigny p. J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652063
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P. Brice P, et al. Among authors: solal celigny p. J Clin Oncol. 1997 Mar;15(3):1110-7. doi: 10.1200/JCO.1997.15.3.1110. J Clin Oncol. 1997. PMID: 9060552 Clinical Trial.
Rituximab by subcutaneous route.
Solal-Celigny P. Solal-Celigny P. Expert Rev Hematol. 2015 Apr;8(2):147-53. doi: 10.1586/17474086.2015.1024651. Expert Rev Hematol. 2015. PMID: 25749209 Review.
Prognosis of follicular lymphomas.
Solal-Celigny P. Solal-Celigny P. Clin Lymphoma. 2005 Jun;6(1):21-5. doi: 10.3816/clm.2005.n.022. Clin Lymphoma. 2005. PMID: 15989702 Review.
Follicular non-Hodgkin's lymphoma.
Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, Solal-Céligny P, Juweid M, Guermazi A. Hayashi D, et al. Among authors: solal celigny p. Clin Radiol. 2010 May;65(5):408-20. doi: 10.1016/j.crad.2010.01.010. Epub 2010 Mar 15. Clin Radiol. 2010. PMID: 20380942 Review.
137 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page